NEW YORK, NY / ACCESSWIRE / September 6, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on CV Sciences, Inc. (OTCQB: CVSI), a company that operates two business segments: a drug development division focused on utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products.
In April of 2018, CVSI shares were trading at $.41 per share and have gained nearly 1000% in the ensuing months. Traded share volumes have increased as well with daily averages in the millions.
Read more about the 2018 developments at CVSI and a product review READ MORE
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/cv-sciences/
CV Sciences is in development of CBD-based potential FDA approved drugs. In December 2015, CV Sciences acquired CanX Inc., a pre-clinical drug development company focused on significant unmet medical needs. The initial drug candidate (CVSI-007) is a chewing gum containing nicotine and synthetic CBD to support the cessation of smokeless tobacco use and addiction.
Get the most recent CVSI financial data and some recent events here READ MORE
Copy and paste to your browser may be required to view the report – https://tradersnewssource.com/cv-sciences/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: [email protected]
SOURCE: Traders News Source